AD-117
Phase 1Small molecule
AD-117 is one of 34 small molecule programs targeting Tics. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
CAB LA
GSKPhase 2
Abexinostat
XXynomic Pharmaceuticals, Inc.
Phase 2
Cocaine Hydrochloride
NNoden Pharma
Phase 3
Anaprazole
SSihuan Pharmaceutical Holdings Group Ltd.
Phase 3
Dostinex
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AD-117. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAddpharma Inc.